why choose us

300×250 Ad Slot

Research Article: Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy

Date Published: 2023-11-07

Introduction:
Lung cancer is the most common cause of cancer mortality worldwide, of which non-small-cell lung cancer (NSCLC) is the main subtype. , Despite the use of molecularly targeted agents, including osimertinib, afatinib, dacomitinib, gefitinib and erlotinib, has achieved important advancements in the treatment of NSCLC, the -year survival rate remains low. , Erlotinib (Eb) is used as the clinical drug either alone or in combination, to treat NSCLC and pancreatic cancers, via inhibiting the phosphorylation of epidermal…

Read more

300×250 Ad Slot